Clinical Trial Update: Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study to determine the maximum tolerated dose of LErafAON in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• LErafAON

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Neoplasms | Phase 1 | Status: COMPLETED